financetom
Business
financetom
/
Business
/
UBS Previews Rogers' Second Quarter
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UBS Previews Rogers' Second Quarter
Jul 2, 2024 11:06 AM

01:44 PM EDT, 07/02/2024 (MT Newswires) -- UBS expects Rogers to report slightly lower volumes but higher margins in both wireless and cable segments, potentially indicating a return to a more rational competitive environment in the near term. Competition (especially through flanker brands) remains intense nationwide in wireless while competition in broadband is more sporadic, depending on the region.

In wireless, UBS is looking for 110K postpaid phone adds (prior UBSe/Q2 2023 170K), while churn remains elevated at +20 bps to 1.07%. Prepaid adds should improve to +35K vs. -8K last year given increased activity in the low-end.

In cable, UBS is looking for 27K broadband adds and 30K video losses, similar to recent trend.

In media, revenue is expected to grow 5%, driven by some improvement in advertising, while EBITDA remains low at $11 million, due to timing of expenses.

"With the anniversary of the Shaw deal, we expect a return to normalized trends with 1.2% revenue and 8% EBITDA growth," writes UBS. The brokerage has largely maintained its 2024 estimates for 8% revenue, 12% EBITDA growth and $3 billion in FCF. Leverage is expected to come down to 4.3x at YE (vs. current 4.7x) and potentially more as $1 billion earmarked for non-core asset sales comes through.

Price: 48.69, Change: -1.91, Percent Change: -3.77

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Knight Therapeutics Applies to Expand Minjuvi Indications in Argentina, Mexico
Knight Therapeutics Applies to Expand Minjuvi Indications in Argentina, Mexico
Mar 17, 2026
08:31 AM EDT, 03/17/2026 (MT Newswires) -- Knight Therapeutics ( KHTRF ) Tuesday said it submitted a supplemental application to the Argentine and Mexican health regulatory agencies, to expand the treatment indications for Minjuvi (tafasitamab). The additional indication for Minjuvi is in combination with lenalidomide and rituximab, to treat adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a)...
Ondas Acquires INDO Earth Moving Ltd. Following its $140 Million Strategic Procurement Tender Award for Military Heavy Engineering Platforms from a Major Military Customer
Ondas Acquires INDO Earth Moving Ltd. Following its $140 Million Strategic Procurement Tender Award for Military Heavy Engineering Platforms from a Major Military Customer
Mar 17, 2026
Acquisition Positions Ondas to Deliver Multi-Year Military Engineering Vehicle Program as a Prime Contractor and Advance Future Robotic Heavy Engineering Platform Capabilities Transaction Expands Ondas Autonomous Systems into Robotic Heavy Engineering Platforms Through Synergies with 4M Defense, Roboteam, and Apeiro Motion Ground Systems $140 Million Military Engineering Vehicle Tender Expected to Begin Revenue Generation in Q2 2026 While Driving Operating...
Sector Update: Consumer Stocks Rise Pre-Bell Tuesday
Sector Update: Consumer Stocks Rise Pre-Bell Tuesday
Mar 17, 2026
09:13 AM EDT, 03/17/2026 (MT Newswires) -- Consumer stocks were rising pre-bell Tuesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) advancing by 0.2% and the State Street Consumer Discretionary Select Sector ETF (XLY) up 0.4%. Atour Lifestyle ( ATAT ) stock was up 2.5% after the company posted higher Q4 adjusted net income and revenue. Academy...
US FDA declines to approve Aldeyra's drug for eye disorder
US FDA declines to approve Aldeyra's drug for eye disorder
Mar 17, 2026
March 17 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' ( ALDX ) drug for a type of eye disease, the company said. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved